SALT LAKE CITY–(BUSINESS WIRE)–Co-Diagnostics, Inc. (Nasdaq: CODX), a diagnostics company with a unique, proprietary platform for the development of molecular diagnostic testing, announced today that it will discuss the Company’s strategic direction and recent corporate developments on Thursday, April 19, 2018 at 2:00 pm ET (1:00 pm CT) in a Lytham Partners’ Virtual Presentation and Fireside Chat. The presentation will be available online with interested parties able to participate by following the webcast links below at the time of the presentation.
The presentation will consist of a brief overview of the Company by Mr. Dwight Egan, Chairman and Chief Executive Officer of the Company, followed by questions from the audience. The event will be moderated by Joe Diaz, managing partner at Lytham Partners.
|
Event: |
Co-Diagnostics, Inc. Virtual Presentation and Fireside Chat |
|||
|
Date: |
Thursday, April 19, 2018 |
|||
|
Time: |
2 pm ET (1 pm CT; 12 pm MT; 11 am PT) |
|||
|
|
||||
| Webcast: |
By accessing the link here. |
|||
A replay of the presentation will be available on demand following the conclusion of the live event.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), and to sell diagnostic equipment from other manufacturers as self-contained lab systems.
Forward-Looking Statements:
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
Company Contact:
Co-Diagnostics, Inc.
Andrew Benson
Co-Diagnostics Investor Relations
801-438-1036
investors@codiagnostics.com
or
Investor Contact:
Lytham Partners, LLC
Joe Diaz, Robert Blum and Joe Dorame
602-889-9700
codx@lythampartners.com